Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2/3 1Phase 2 1

Status

Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 40Breast Neoplasms 12Prostatic Neoplasms 11Fallopian Tube Neoplasms 10Pancreatic Neoplasms 7Neoplasms 7Endometrial Neoplasms 7Glioblastoma 6Neoplasm Metastasis 5Carcinoma, Ovarian Epithelial 5Triple Negative Breast Neoplasms 4Lung Neoplasms 4Glioma 4Small Cell Lung Carcinoma 3Mesothelioma 3Cystadenocarcinoma, Serous 3Cholangiocarcinoma 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Recurrence 2Mesothelioma, Malignant 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma 2Brain Neoplasms 2Biliary Tract Neoplasms 2Uveal Melanoma 1

Interventions

niraparib 3pembrolizumab 1Paclitaxel 1Diphenhydramine 1Dexamethasone 1Cimetidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Cystadenocarcinoma, Serous × niraparib × Clear all
NCT04159155 2025-08-12

CAN-STAMP

University Health Network, Toronto

Phase 2/3 Terminated
11 enrolled
Gynecologic

Endometrial Neoplasms, Cystadenocarcinoma, Serous

NCT05289648 2024-12-19

NIREC

Sir Mortimer B. Davis - Jewish General Hospital

Phase EARLY_PHASE1 Withdrawn
Gynecologic

Uterine Neoplasms, Endometrial Neoplasms, Cystadenocarcinoma, Serous

NCT04716686 2024-01-05

Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

Shandong University

Phase 2 Recruiting
83 enrolled
Gynecologic

Endometrial Neoplasms, Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡